Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Non-Current Liabilities (2016 - 2025)

Fate Therapeutics' Other Non-Current Liabilities history spans 14 years, with the latest figure at $283000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 94.42% year-over-year to $283000.0; the TTM value through Dec 2025 reached $283000.0, down 94.42%, while the annual FY2025 figure was $283000.0, 94.42% down from the prior year.
  • Other Non-Current Liabilities reached $283000.0 in Q4 2025 per FATE's latest filing, down from $6.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $24.2 million in Q4 2021 to a low of $283000.0 in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $4.1 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 94.51% in 2021, then surged 1876.12% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $24.2 million in 2021, then plummeted by 84.02% to $3.9 million in 2022, then tumbled by 65.14% to $1.3 million in 2023, then surged by 276.67% to $5.1 million in 2024, then crashed by 94.42% to $283000.0 in 2025.
  • Per Business Quant, the three most recent readings for FATE's Other Non-Current Liabilities are $283000.0 (Q4 2025), $6.6 million (Q3 2025), and $5.6 million (Q2 2025).